Oxford's OrganOx raises £25m to fuel expansion including US push
Oxford-based medical company OrganOx was advised by Penningtons Manches Cooper on its £25 million growth round led by Lauxera Capital Partners.
Proceeds from the fundraise will enable OrganOx to significantly expand its commercial footprint across strategically key areas of the business. This includes expanding the customer-facing team in the United States due to high interest and adoption of the OrganOx technology.
The Penningtons Manches Cooper team advising OrganOx was led by corporate partner James Went, with support from senior associate Lindsay Chadwick and corporate tax partner Kathy Hills.
James said: “We’ve worked with OrganOx from day one of their journey - it is such a fantastic company and team, making a real difference to patients. It was great working with them on this round and we look forward to seeing them continue to expand the use of their exciting technology across the world.”
Visit Hampshire Biz News for bright, upbeat and positive business news from the county
OrganOx is a medical technology company that develops medical devices used for sustaining donor organs outside the body using blood at normal body temperatures. The company has supported over 2,500 liver transplants in Europe, the US, and Australia.
Craig Marshall, chief executive officer at OrganOx, said: “We are thrilled to have Lauxera Capital Partners at the table. Their collective experiences will be invaluable to OrganOx as we execute our commercial strategy in Europe, North America and Australia.
''I’d also like to thank James Went and Lindsay Chadwick and the rest of the Penningtons Manches Cooper team for their hard work, insights and advice on this transaction and helping us continue to deliver on our vision to make organs more widely available to patients who need them around the world.”
Read more - Dorset's Hall & Woodhouse announces annual results